Pink SheetAurobindo and MSN Labs are facing a wait of more than a decade to launch their proposed generic versions of Acadia Pharmaceuticals ’ Nuplazid (pimavanserin tartrate) 34mg capsules after a US feder
Generics BulletinTeva is aiming to build a long-acting injectable schizophrenia franchise worth between $1.5bn and $2bn in annual sales at its peak, bolstered by a high unmet need and poor adherence for oral medicatio
Generics BulletinAs the name of the event suggested, Teva’s 29 May Innovation & Strategy Day presentation focused chiefly on plans to expand its branded medicines business, including a roadmap to achieve $2.5bn in
Generics BulletinTeva has filled a gap in its non-US oncology portfolio after inking a license and supply agreement with Prestige BioPharma to commercialize the Singaporean firm’s Tuznue (trastuzumab) biosimilar to Ro